Journal
Peptide Science, Research and Recovery
In-depth stories, reports and perspectives on performance, recovery and longevity.
Retatrutide After Phase 3: What Four Trial Readouts Actually Showed
Between December 2025 and July 2026, four Phase 3 trials reported topline results. The compound moved from a promising signal to a late-stage asset with data across obesity, diabetes, and CVD.
TB-500 and Thymosin Beta-4: Why the Fragment Isn't the Molecule
Most writing about TB-500 cites research about Thymosin Beta-4. Those are not the same thing, and the gap between them is the most important fact about this compound.
Peptide Regulation in 2026: What Actually Changed
The regulatory landscape shifted through three separate mechanisms: a compounding decision in 2023, shortage resolutions in 2024-25, and an enforcement campaign in 2026.
Collagen Peptides: The One With Actual Human Trials
Unusually for this space, the core findings come from controlled trials in people. Effect sizes are modest, and the protocol matters more than the product.
GLP-1 Agonists and the Metabolic Flexibility Question
The open question isn't whether these drugs work—it's what they leave behind. Do they improve underlying flexibility or just reduce the load on a broken system?
BPC-157: A Deep Preclinical File and an Empty Clinical One
No completed modern controlled human trial exists. Everything describing efficacy comes from animal models or cell culture. Both of these facts are true at once.
Get the next post in your inbox
One thoughtful email when we publish. No spam, no hype, just peptide science you can trust.